Phaseline

Targets › MMP2

MMP2 (72 kDa type IV collagenase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2027.

Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. (UniProt, P08253)

Open in Phaseline: the race on MMP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterChlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes
CAR-T cell therapy with chlorotoxin tumor-targeting domain recognizing MMP2
MMP2Phase 1Recurrent GlioblastomaMay 2027

Conditions

Recurrent Glioblastoma (1)

Modalities

other (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.